Positioning itself as a flexible local CRO with an in-depth knowledge of the Mexican market, iLS Clinical Research CEO, Alejandro Arias, shares his insights on how to be the ideal partner for international expansion. He speaks about the company’s milestones and background, navigating through the challenges of the Mexican CRO environment, as well as leveraging their corporate culture of agility and flexibility to garner clinical trial success in the international milieu.
Mr. Arias, you have quite an impressive profile working in management positions in leading clinical research companies such as Covance, PPD, and Quintiles. What are the factors that triggered you to found your own clinical research organization, iLS Clinical Research in 2015?
"Clinical trials are a critical step in the development of new molecules because in many cases it is the prerequisite before any product can be marketed. Although having this necessity is universal, the processes, requirements and protocols differ in various countries."
